Michael Jacobsen Biography and Net Worth

CAO of Omeros

Mr. Jacobsen joined Omeros in August 2013 as our vice president of finance and has served as our chief accounting officer and treasurer since October 2013. Prior to joining Omeros, Mr. Jacobsen served as vice president of finance at Sarepta Therapeutics from September 2011 to May 2013 and as its chief accounting officer from September 2011 to December 2012. From April 2007 to August 2011, Mr. Jacobsen was vice president and chief accounting officer at ZymoGenetics. Prior to his service with ZymoGenetics, Mr. Jacobsen held various roles at ICOS Corporation, including senior director of finance and corporate controller. From April 1995 to October 2001, Mr. Jacobsen held vice president of finance or chief financial officer roles at three companies in the software, computer hardware and internet retailing industries, two of which were publicly traded. Mr. Jacobsen is a certified public accountant and received his bachelor’s degree in accounting from Idaho State University.

What is Michael A. Jacobsen's net worth?: The estimated net worth of Michael A. Jacobsen is at least $197,280.00 as of February 22nd, 2021. Mr. Jacobsen owns 24,000 shares of Omeros stock worth more than $197,280 as of March 31st. This net worth evaluation does not reflect any other investments that Mr. Jacobsen may own. Learn More about Michael A. Jacobsen's net worth.
How do I contact Michael A. Jacobsen?: The corporate mailing address for Mr. Jacobsen and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at ir@omeros.com. Learn More on Michael A. Jacobsen's contact information.
Has Michael A. Jacobsen been buying or selling shares of Omeros?: Michael A. Jacobsen has not been actively trading shares of Omeros over the course of the past ninety days. Most recently, Michael A. Jacobsen sold 8,100 shares of the business's stock in a transaction on Monday, February 22nd. The shares were sold at an average price of $23.28, for a transaction totalling $188,568.00. Following the completion of the sale, the chief accounting officer now directly owns 24,000 shares of the company's stock, valued at $558,720. Learn More on Michael A. Jacobsen's trading history.
Who are Omeros' active insiders?: Omeros' insider roster includes Gregory Demopulos (CEO), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.

Michael A. Jacobsen Insider Trading History at Omeros

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2021	Sell	8,100	$23.28	$188,568.00	24,000
2/19/2021	Sell	10,000	$22.64	$226,400.00	24,000
2/10/2021	Sell	1,900	$22.49	$42,731.00	15,900
1/19/2021	Sell	9,500	$19.95	$189,525.00	4,000
5/15/2018	Sell	23,792	$23.80	$566,249.60	19,480
1/3/2018	Sell	1,020	$22.45	$22,899.00	8,520
6/16/2017	Sell	12,000	$24.95	$299,400.00	19,500
6/15/2017	Sell	24,000	$21.20	$508,800.00	2,650

Michael A. Jacobsen Buying and Selling Activity at Omeros

Omeros Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $8.22

$8.09

$8.53

50 Day Range

MA: $8.69

$7.04

$9.61

2 Week Range

Now: $8.22

$2.61

$13.60

Volume

767,992 shs

Average Volume

540,300 shs

Market Capitalization

$476.35 million

P/E Ratio

N/A

Dividend Yield